IXI
NEUTRALIXICO Announces Change in Shareholder
The healthcare company announces a change in the investment manager and name of one of its shareholders, with no impact on its own operations.
IXICO
9.00GBX
-7.22%
Market Cap
8.34M
Volume
89.84k
264% of avg
P/E Ratio
-0.04
EPS (TTM)
-2.1
Beta
0.62
Day Range
9.17p - 9.50p
52 Week Range
6.45p9.00p13.00p
9.00p
Upcoming Events
20 May 2025
Release of IXICO's interim results
IXI
NEUTRALIXICO Provides Update on Interim Results and Investor Presentation
The healthcare technology company will release its interim results and host an investor presentation next month.
IXI
VERY GOODIXICO Delivers Strong First Half Performance
The medical imaging analytics company reports robust first-half performance, with revenues up 26% and improved profitability, positioning it well for the remainder of the year.
IXI
GOODIXICO Secures New Contracts in Alzheimer's and Huntington's Disease
The healthcare data analytics firm has secured new contracts worth over £0.5 million to provide imaging services for Alzheimer's and Huntington's disease research, highlighting its market-leading position.
IXI
GOODIXICO's AI Imaging Platform Validated by Huntington's Disease Consortium
The healthcare company has made significant progress in validating its AI imaging platform for Huntington's Disease, generating new insights and positioning its technology for increased commercial adoption.
IXI
NEUTRALIXICO Grants Share Options to Executives
The healthcare technology company has granted share options to its top executives, with shareholder approval.
IXI
GOODIXICO Expands Neuroimaging Capabilities with PETNET Solutions Partnership
Healthcare data analytics firm IXICO partners with PETNET Solutions to expand its neuroimaging services.
IXI
GOODIXICO Secures Major US Clinical Trial Contract for Huntington's Disease
The healthcare technology company has secured a major new contract to provide imaging services for a Huntington's Disease clinical trial, reinforcing its commercial momentum and strategic progress.
IXI
NEUTRALIXICO Announces Share Option Award and Director Dealings
The medical imaging analytics company announces a share option award to its Chief Scientific Officer and a director dealing by the Chief Financial Officer.
IXI
NEUTRALIXICO Reports Mixed 2024 Results, Signals Transition to Growth
The neuroscience imaging firm reported mixed annual results, with revenue decline offset by H2 improvement and a growing order book. A new CEO and AI platform launch signal a potential turnaround.